A Message from Veracyte’s CEO About COVID-19     Learn More
A Message from Veracyte’s CEO About COVID-19     Learn More
Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 30, 2020-- Veracyte, Inc ., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the Journal of Clinical Oncology (JCO).
Toggle Summary Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier
RNA sequencing and novel machine learning algorithms generate a test that improves lung cancer diagnosis using brushings from the main lung airway SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 22, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of a manuscript detailing


Date Event Details
Summary Toggle Nov 2, 2020 4:30 PM EST
Veracyte Third Quarter 2020 Financial Results Webcast


Title Documents

Corporate Presentation August 2020